Medtronic's next generation cardiac resynchronisation therapy pacemakers gain CE mark

Medtronic announced Friday that it received CE mark for a suite of next generation quadripolar cardiac resynchronisation therapy pacemakers (CRT-Ps) that allow patients to receive magnetic resonance imaging (MRI) scans in either 1.5 or 3 Tesla machines. Medtronic added that the Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan and Solara Quad CRT-P MRI SureScan will be launched next month.

David Steinhaus, general manager of the Heart Failure business, remarked that the devices, which are not approved in the US, "include advanced, smart technologies that allow physicians to provide each patient with the appropriate therapy specific to his or her individual needs, all while offering access to advanced life-saving MRI technologies."

Specifically, according to Medtronic, the Percepta Quad CRT-P features the EffectivCRT diagnostic that determines the effectiveness of each left ventricular pace, and the EffectivCRT during atrial fibrillation (AF) algorithm that adjusts pacing rates "without adversely affecting the average heart rate." Meanwhile the VectorExpress 2.0 automated in-office test reduces lead programming to two minutes, while helping "physicians select optimal pacing configurations for each patient."

Medtronic added that the Percepta and Serena devices also feature Multiple Point Pacing along with the AdaptivCRT algorithm, "which reduces a patient's odds of a 30-day heart failure readmission by 59 percent and has demonstrated a 46 percent reduction in AF risk compared to echo-optimised biventricular pacing."

Medtronic recently reported that third-quarter fiscal 2017 revenue grew 5 percent year-over-year to $7.3 billion, which included a 7 percent rise in Cardiac Rhythm & Heart Failure sales to $1.4 billion.

Did you like this article?